share_log

HC Wainwright & Co. Maintains Buy on Annovis Bio, Lowers Price Target to $23

Benzinga ·  May 13 19:49

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Annovis Bio (NYSE:ANVS) with a Buy and lowers the price target from $30 to $23.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment